financetom
RGEN
financetom
/
Healthcare
/
RGEN
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Repligen CorporationRGEN
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.

It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths.

Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.

The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.

Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Latest News >
Salesforce forecasts second-quarter revenue below estimates
Salesforce forecasts second-quarter revenue below estimates
May 29, 2024
(Reuters) - Salesforce ( CRM ) forecast second-quarter revenue below Wall Street expectations on Wednesday, on weak client spending on its cloud and enterprise business products in an uncertain economy, sending its shares down 9% in extended trading. The company forecast revenue between $9.20 billion and $9.25 billion compared with estimates of $9.37 billion, according to LSEG data. Salesforce's (...
--Pure Storage Guides For Q2 Revenue of $755 Million, vs CIQ Analyst Consensus of $752 Million; FY 2025 Revenue Seen at $3.1 Billion, vs Consensus of $3.1 Billion
--Pure Storage Guides For Q2 Revenue of $755 Million, vs CIQ Analyst Consensus of $752 Million; FY 2025 Revenue Seen at $3.1 Billion, vs Consensus of $3.1 Billion
May 29, 2024
04:11 PM EDT, 05/29/2024 (MT Newswires) -- Price: 62.20, Change: -0.81, Percent Change: -1.28 ...
--C3.ai Guides For Q1 Revenue of $84-$89 Million, vs CIQ Analyst Consensus of $86 Million; FY 2025 Revenue Seen at $370-$395 Million, vs Consensus of $368 Million
--C3.ai Guides For Q1 Revenue of $84-$89 Million, vs CIQ Analyst Consensus of $86 Million; FY 2025 Revenue Seen at $370-$395 Million, vs Consensus of $368 Million
May 29, 2024
04:09 PM EDT, 05/29/2024 (MT Newswires) -- Price: 27.10, Change: +3.18, Percent Change: +13.29 ...
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing
May 29, 2024
04:11 PM EDT, 05/29/2024 (MT Newswires) -- Timothy J Scannell, Director, on May 28, 2024, sold 3,300 shares in Insulet ( PODD ) for $596,970. Following the Form 4 filing with the SEC, Scannell has control over a total of 42,586 shares of the company, with 42,586 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1145197/000112760224016771/xslF345X03/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved